Sanofi halts development of Nurix-partnered STAT6 degrader, sending Nurix shares lower
The setback fuels analyst debate over the prospects of drugs designed to degrade the hard-to-target STAT6 protein.
Read at Biopharmadive →Full coverage · 9 outlets
- Biopharmadive · lead
- Fierce BiotechSanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
- BioPharma DiveSanofi stops development of Nurix-partnered immune drug
- BioSpaceSanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
- GuruFocusNurix Therapeutics (NRIX) Shares Slip Premarket After Sanofi Hal
- BigGo FinanceNurix Shares Drop 35% After Sanofi Scraps Oral Immunology Drug
- PluangSanofi halts development of Nurix's STAT6 degra...
- kalkine.caWhat Drove Nurix Therapeutics (NASDAQ:NRIX) Down 41.91% Once Sanofi Halted Its STAT6 Degrader Study?
- BiospaceSanofi’s axing of Nurix STAT6 program ‘not a target-related issue’